Author: [email protected]

Release – Kodiak Commences Additional Metallurgical Testing Focused on Flowsheet Development & Optimization

Posted on by [email protected]

October 22, 2026 – Vancouver, British Columbia – Kodiak Copper Corp. (the “Company” or “Kodiak”) (TSX-V: KDK, OTCQX: KDKCF, Frankfurt: 5DD1) today reports that it has commenced an additional metallurgical testwork program, for its 100% owned MPD copper-gold porphyry project in southern British Columbia.

The testwork program will focus on flowsheet development and optimization and build on the test results received earlier this year (see news release here). It will include samples from all seven deposits that comprise the Mineral Resource Estimate at MPD: Gate, Ketchan, Man, Dillard, West, Adit and South (see Figure 1). Sample selection was designed to be representative of the mineralization, grade, lithology, and spatial variability across each deposit. Four composite samples representing the Southern Area (South, West and Adit), Northern Area (Man and Dillard), Ketchan and Gate will be tested. Testing will include mineralogy, comminution, gravity testwork for gold, flotation rougher and cleaner optimization, locked cycle testing and concentrate quality assessment. The results from the program are expected in Q1 2027.

Claudia Tornquist, President and CEO of Kodiak said,

“As we continue to grow the mineral resource at MPD through exploration, we are also advancing our metallurgical testwork to further de-risk the project and strengthen the foundation for future economic studies. Our metallurgical results to date are very encouraging, and this next phase of work is designed to expand on those positive findings. The program will focus on optimizing metal recoveries, particularly for gold, and produce valuable information on rock properties and hardness. Together with our ongoing exploration program and planned resource update in early 2027, this work represents another important step in unlocking the value of MPD for our shareholders.”

Kodiak has engaged Fuse Advisors Inc., Part of SLR (“Fuse”) to design and manage this metallurgical testwork program, with technical guidance from Kodiak advisor Mike Westendorf. Fuse is a mining consultancy with extensive experience across a wide range of deposit types and metals, including many porphyry copper projects in British Columbia. The laboratory work will be conducted in Parksville at Blue Coast Research Ltd (“Blue Coast”) under the supervision of Fuse Metallurgist Renee Goold, P.Eng, an independent Qualified Person as defined by National Instrument 43-101. Blue Coast is a leading provider of metallurgical testing services for the global mining industry.

Ms Goold has reviewed this news release and approved the technical information pertaining to the metallurgical work. Dave Skelton, P.Geol, Vice President Exploration and a Qualified Person as defined by National Instrument 43-101, has reviewed, and approved the technical information contained in this release.

On behalf of the Board of Directors

Kodiak Copper Corp.
 
Claudia Tornquist
President & CEO

For further information contact:
Nancy Curry, VP Corporate Development
[email protected]
+1 (604) 646-8362

Release – T3 Defense Delivers Mobile UAV Command-and-Control Vehicle to Israeli HLS Operator

Posted on by [email protected]

October 22, 2026 09:00 ET

NEW YORK and NETANYA, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) — T3 Defense Inc. (Nasdaq: DFNS) (“T3 Defense” or the “Company”), a defense company that acquires and operates mission-critical defense businesses, today announced that its wholly owned subsidiary, Rimon Agencies Ltd. (“Rimon”), has delivered a drone-integrated mobile command-and-control (C2) vehicle to B.K. Vision Ltd. (“B.K. Vision”), a leading Israeli provider of homeland security (HLS) services. This delivery marks the transition from product introduction to customer deployment, representing the first unit delivered to a customer under the mobile unmanned aerial vehicle (UAV) and counter-UAV (C-UAV) platform line introduced by Rimon in August 2026.

Built by Rimon’s UAV Platforms project division, the fully integrated platform provides B.K. Vision with a self-contained base from which to launch, control and recover a UAV and manage a response where no fixed infrastructure exists.

“A command-and-control vehicle is central to a cohesive operation where power, communications, aircraft and operators all come together,” said Itamar Shimoni, Chief Executive Officer of Rimon. “We delivered B.K. Vision a vehicle that is ready to operate the day it arrives, bringing these capabilities together in a single mobile platform. As we continue to see an increasing need across defense and homeland security organizations in Israel and abroad, our focus is on applying Rimon’s engineering and integration capabilities to the operational requirements of additional defense and homeland security customers.”

“In August we said the drone threat had moved faster than the infrastructure built to answer it,” said Menny Shalom, Chairman and Chief Executive Officer of T3 Defense. “This delivery is that infrastructure, built and deployed. As the first command-and-control vehicle shipped under Rimon’s new platform line, it marks the transition from product introduction to customer delivery. Our focus is on translating this milestone into additional orders and building a repeatable business around mission-ready products.”

About Rimon

Rimon is a bespoke engineering and systems integration company that develops mission-ready infrastructure platforms for defense, homeland security, and emergency response operations. The company imports, distributes, and upgrades mobile power systems, elevated sensor masts, and builds integrated mission vehicles that support surveillance, communications, and command systems operating in environments where permanent infrastructure is unavailable. By engineering systems around real operational requirements, Rimon enables critical technologies to be deployed rapidly and operate reliably in demanding field conditions.

About T3 Defense Inc.

T3 Defense Inc. (Nasdaq: DFNS) is a defense company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with strong customer relationships and solid order backlogs, often capacity- and resource-constrained, in specialized areas such as drones and autonomous vehicles, counter-drone systems, advanced manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and strategy, and decentralized day-to-day operations, T3 Defense aims to strengthen essential defense capabilities and build long-term value. For more information, visit www.t3dfns.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding the anticipated capabilities, configurations and availability of the command-and-control vehicles and trailers described herein; expected demand from defense and homeland security customers; the potential for additional orders or recurring revenue; and the Company’s growth strategy. These statements are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results to differ materially, including the risk that a single delivery is not indicative of future orders; the absence of orders for the configurable platforms described herein; customer qualification, procurement timing and program funding; dependence on a limited number of customers; manufacturing execution, capacity and supply-chain risks; competitive and geopolitical conditions, including conditions in Israel; the Company’s liquidity and capital resources; the Company’s ability to maintain compliance with Nasdaq listing requirements; the integration of acquired businesses; and other risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contact Us:

T3 Defense Inc.
575 5th Avenue
New York, NY 10017
[email protected]
www.t3dfns.com

Rimon
Chen Ganzer
[email protected]

Investor Relations
The Equity Group Inc.
Lena Cati
[email protected]
+1 212 836-9611

Val Ferraro
[email protected]
+1 212 836-9633

Unicycive Therapeutics (UNCY) – NDA Resubmission Accepted For FDA Review

Posted on by [email protected]


Thursday, October 22, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

OLC Resubmission Given March 25, 2027 PDUFA Date. Unicycive announced that the FDA has accepted its NDA (New Drug Application) resubmission for OLC (oxylanthanum carbonate) for review. This follows the 30-day period after resubmission in which the FDA determined that it was sufficiently complete for review. The application received a PDUFA (Prescription Drug User Fee Act) date of March 25, 2027. This is the date the FDA must respond to the application by statute and aligns with the TDAPA program deadlines.

The NDA Contains Data From A New Manufacturing Partner. As we had expected, the resubmission was classified as Class 2 and received a six-month review. The CMC (Chemistry, Manufacturing, and Controls) section includes product manufacturing data from a new third-party manufacturing partner. The FDA inspected this manufacturer’s plant in March 2024 and gave a “No Action Indicated” status, the equivalent of a passing grade.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – Proof of Concept

Posted on by [email protected]


Thursday, October 22, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Proof. It didn’t take long for SKYX Platforms and new subsidiary Deako to supply proof of concept on one of the key elements of the merger: i.e., cross-selling. Yesterday, SKYX announced that it will supply over 80,000 units of its advanced technologies to over 1,000 homes for Maronda Homes. We believe this announcement will be the first of many.

Details. The Company expects to deliver over 80,000 units of its advanced plug-and-play and smart home technologies to over 1,000 Maronda Homes residences in several states, including Ohio, Georgia, Maryland, and Pennsylvania. If the contract is similar to the $50/unit revenue previously disclosed, the contract would represent some $4 million in revenue.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

US Jobless Claims Fall to 194,000 Near 57-Year Low as Fed Faces Interest Rate Decision

Posted on by [email protected]

New applications for unemployment benefits in the United States fell to one of their lowest levels in nearly six decades, offering fresh evidence that American businesses are holding onto workers despite slower hiring, elevated borrowing costs, and persistent inflation concerns.

According to data released Thursday by the Labor Department, initial jobless claims declined by 6,000 to a seasonally adjusted 194,000 for the week ending October 17. The figure came in below economists’ expectations of 200,000 and marked the sixth consecutive week that claims remained at or below that level.

The latest reading approaches the 189,000 claims recorded in July, the lowest level since 1969. The four-week moving average, which helps smooth weekly fluctuations, declined by 1,000 to 197,750, reinforcing signs that layoffs remain historically low.

The report provides a potentially reassuring signal for investors concerned about the strength of the U.S. economy. Despite higher energy prices, trade uncertainty, and elevated interest rates, employers have largely avoided widespread layoffs.

However, the labor market presents a more complicated picture beneath the headline numbers.

While businesses are retaining existing employees, many remain cautious about expanding their workforces. Economists have characterized the current environment as a “low-hire, low-fire” labor market, where job security remains relatively strong but opportunities for unemployed workers are more limited.

That distinction was evident in continuing unemployment claims, which measure the number of Americans receiving benefits after their initial week. Continuing claims increased by 25,000 to approximately 1.73 million for the week ending October 10.

The increase suggests that some unemployed Americans may be taking longer to find new positions, even as the overall pace of layoffs remains subdued.

Recent employment data further illustrates the uneven recovery in hiring. U.S. employers added just 29,000 jobs in September, following a stronger gain of 133,000 in August. The unemployment rate stood at 4.2%, indicating that the labor market remains relatively stable despite slower job creation.

For Wall Street, the latest unemployment figures arrive at a critical moment for Federal Reserve monetary policy.

The central bank raised its benchmark interest rate by a quarter percentage point in September, bringing the target range to 3.75%–4.00%. Policymakers continue balancing the need to contain inflation against the risk that restrictive borrowing costs could eventually weaken economic activity.

Higher energy prices linked to the conflict involving Iran have complicated that calculation by increasing inflationary pressure on businesses and consumers.

Historically low unemployment claims could give the Federal Reserve additional flexibility to maintain elevated interest rates while monitoring inflation. Economists generally expect policymakers to leave rates unchanged at their upcoming meeting, although another increase remains possible later this year.

The implications extend across financial markets. Interest-rate expectations influence Treasury yields, mortgage costs, corporate borrowing, and equity valuations, particularly among growth-oriented technology companies.

Small-cap companies can also be sensitive to changes in financing conditions because many rely more heavily on external capital to support expansion, research, and operations.

For investors, the latest report offers encouraging evidence that the U.S. economy continues to avoid widespread job losses. Nevertheless, the combination of limited hiring, persistent inflation risks, and higher borrowing costs leaves important questions about the sustainability of economic growth.

With the Federal Reserve’s next policy decision approaching, investors will closely monitor upcoming inflation and employment reports for clues about the direction of interest rates through the remainder of 2026.

Oil Prices Surge Above $110 as U.S.-Iran Tensions Raise Fears of Escalation After Midterms

Posted on by [email protected]

Oil prices surged Thursday as investors weighed reports that the United States and Israel could intensify military operations against Iran following the November midterm elections, raising concerns about additional disruptions to global energy supplies and renewed inflationary pressure.

Brent crude futures climbed above $111 per barrel during early trading on October 22, approaching a five-month high, while U.S. West Texas Intermediate crude rose toward $100. The gains reflected growing uncertainty surrounding the Middle East conflict and the potential consequences for oil production, shipping routes, and global economic growth.

According to reports citing The New York Times, U.S. and Israeli officials have been considering expanded military operations targeting Iranian energy infrastructure and other strategic facilities after the November 3 elections. The reported plans remain uncertain, and no final decision on additional military action has been publicly confirmed.

The developments have intensified concerns surrounding the Strait of Hormuz, a critical shipping passage connecting major Persian Gulf oil producers with international markets. Disruptions to tanker traffic through the waterway have already constrained energy shipments, contributing to higher crude prices and increased volatility across commodity markets.

Recent attacks have added to the uncertainty. Iran-aligned Houthi forces launched strikes against targets in Saudi Arabia, including energy-related infrastructure, while additional incidents involving vessels in the Persian Gulf have heightened concerns about regional security.

The combination of military tensions and shipping disruptions has created a significant geopolitical risk premium in oil prices, with traders increasingly focused on the possibility of prolonged supply shortages.

Energy markets received additional support from U.S. inventory data released Wednesday. The Energy Information Administration reported that domestic crude inventories declined by approximately 3.1 million barrels during the previous week, exceeding analysts’ expectations for a smaller reduction.

The larger-than-expected drawdown suggests that available supplies remain tight, adding upward pressure to prices at a time when geopolitical developments are already limiting market confidence.

For investors, rising crude prices have implications extending well beyond the energy sector. Higher oil costs can increase gasoline and diesel prices, raise transportation expenses, and push up production costs for businesses across the economy.

Those pressures could complicate the Federal Reserve’s efforts to contain inflation. If energy prices remain elevated, policymakers may face additional challenges in determining when borrowing costs can move lower without reigniting broader price pressures.

The developments are particularly relevant for smaller companies, which may have less flexibility to absorb higher operating expenses or secure financing during periods of elevated interest rates.

At the same time, stronger oil prices can create opportunities for energy producers. Companies operating in North American oil and natural gas markets may benefit from improved commodity pricing, although production costs, hedging arrangements, and individual operating conditions influence their financial performance.

Among companies followed by Noble Capital Markets, InPlay Oil Corp. (TSX: IPO) operates in the Canadian oil and natural gas sector, while Alliance Resource Partners (NASDAQ: ARLP) maintains significant exposure to domestic energy markets through its coal operations and related interests. Their businesses illustrate different areas of the energy industry that investors may evaluate as commodity markets respond to geopolitical developments.

However, higher energy prices are not universally positive for the sector. Companies dependent on fuel-intensive transportation, manufacturing, and logistics may experience additional margin pressure if elevated prices persist.

The coming weeks could prove important for global oil markets as investors monitor diplomatic negotiations, military developments, and the outlook for energy shipments through the Persian Gulf.

For now, the combination of geopolitical uncertainty and tightening inventories suggests that oil prices could remain volatile, with significant implications for inflation, corporate earnings, and financial markets heading into the final months of 2026.

Anthropic IPO Could Target $2 Trillion Valuation as AI Giant Prepares Public Filing

Posted on by [email protected]

Anthropic, the artificial intelligence company behind the Claude chatbot, could publicly file its initial public offering prospectus as early as Friday, October 23, setting the stage for what could become one of the largest stock market debuts in history. The anticipated filing comes as investors increasingly question whether the explosive growth of artificial intelligence can justify the industry’s enormous infrastructure spending and soaring valuations.

According to Yahoo Finance, which cited three people familiar with the company’s plans, Anthropic is preparing to make its S-1 registration statement publicly available following a confidential submission to the Securities and Exchange Commission in June. The filing would represent a significant step toward a potential November IPO, although the company has not confirmed the timing or final offering terms.

Wall Street has reportedly discussed a valuation approaching $2 trillion, with the offering potentially raising as much as $100 billion. If achieved, those figures would make Anthropic’s debut a defining moment for the AI investment boom and provide public-market investors with direct exposure to one of the industry’s leading developers of advanced artificial intelligence models.

Founded in 2021 by former OpenAI researchers, including CEO Dario Amodei and President Daniela Amodei, Anthropic has emerged as a major competitor in generative AI. Its Claude family of models powers enterprise applications, coding tools, and workplace automation, positioning the company to benefit from growing corporate demand for AI-powered productivity solutions.

Anthropic’s revenue growth has been extraordinary. According to financial information reported by The Wall Street Journal, the company generated approximately $16.3 billion in revenue during the first six months of 2026. Revenue reportedly accelerated further during the third quarter, reflecting rapid adoption of its products among business customers.

However, that growth has come with substantial financial costs. Reports indicate Anthropic recorded a net loss exceeding $80 billion during the first half of 2026, although much of that figure was attributed to accounting charges associated with financing arrangements rather than direct operating expenses.

The company also faces enormous computing requirements. Training and operating advanced AI models requires extensive access to specialized chips, data centers, and cloud infrastructure. Anthropic maintains major relationships with technology giants including Amazon and Alphabet’s Google, while competing for computing resources in an increasingly capital-intensive industry.

Those spending requirements are becoming a central concern for investors. AI infrastructure companies have experienced heightened volatility in recent weeks as Wall Street evaluates whether future revenue growth will be sufficient to support rising debt levels, expensive computing contracts, and aggressive expansion plans.

The potential Anthropic IPO could arrive during a period of increasing selectivity in the public markets. Recent weakness in AI-related stocks and disappointing technology IPO performances suggest investors are becoming more cautious about companies carrying ambitious valuations without established profitability.

For investors, Anthropic’s public prospectus would provide a more detailed view of the company’s financial performance, operating costs, customer concentration, and long-term capital commitments. Those disclosures could help establish new valuation benchmarks for the broader artificial intelligence sector, including competitors such as OpenAI.

The offering could also influence other technology companies considering public listings. A successful debut might encourage additional AI businesses to enter the market, while weaker demand could signal that investors are becoming less willing to finance rapid expansion at premium valuations.

Although Anthropic has not announced an official IPO date, share price, or stock ticker, the expected public filing represents a major development for the technology industry. As artificial intelligence companies transition from private funding toward public ownership, investors will increasingly demand evidence that extraordinary revenue growth can translate into sustainable profitability.

Release – Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

Posted on by [email protected]

October 21, 2026 7:05am EDT

Primary Logo

MOUNTAIN VIEW, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026. The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027.

“We are pleased that the FDA has accepted the resubmission of our NDA for OLC and assigned a PDUFA date,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “This resubmission includes CMC data from a new third-party drug product manufacturing vendor. The new vendor’s facility was last inspected by the FDA in March 2024 and received ‘No Action Indicated’ status. We hope to continue working with the FDA toward potential approval of this important medication to patients with CKD on dialysis who need additional treatment options for managing hyperphosphatemia.”

The Company does not know whether the FDA will decide to conduct a pre-approval inspection of the new third-party DP vendor. Additionally, if the original third-party manufacturing vendor is inspected in the near term and finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to seek FDA alignment on a shorter approval timeline.

The Company resubmitted the NDA following the second CRL, which cited deficiencies previously identified at the original third-party manufacturer of the drug product, which the FDA had not been able to re-inspect during the prior submission review.

The timing and outcome of any FDA inspection of the original third-party vendor will be determined solely by the FDA.

The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, as well as CMC data. The FDA did not raise any concerns regarding OLC’s preclinical or clinical data, including safety data, included in the original NDA submission.

About Oxylanthanum Carbonate
OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.

About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.

1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145.

About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; Unicycive’s clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; Unicycive’s dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of its NDA; the risk that the inspection of the original or new third-party manufacturing vendor may not occur within a timeframe that benefits its regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm its financial condition and increase its costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of its products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts:
Kevin Gardner
LifeSci Advisors
[email protected]

Media Contact:
Unicycive Therapeutics
[email protected] 

SOURCE: Unicycive Therapeutics, Inc.

Release – BODi Launches INSANITY “Liquid Shock” Energy Drink Designed For Sharper Focus, Improved Reaction Time, Physical Performance and a Huge Jolt of Energy

Posted on by [email protected]

October 21, 2026

Formulated to help unlock extreme mental and physical performance, taking you from fatigued to a colossal jolt of energy with sharper focus, zero sugar and just five calories per can

EL SEGUNDO, Calif.–(BUSINESS WIRE)– BODi (NASDAQ: BODI), the proactive wellness company delivering nutrition, supplements and proven fitness programs that help people take control of their health inside and out, today announced the launch of INSANITY Liquid Shock Energy Drink, a zero-sugar, ready-to-drink energy beverage designed to fuel demanding days when ordinary energy isn’t enough. From intense workouts to extreme challenges and long shifts, INSANITY Liquid Shock Energy Drink delivers sustained energy and sharper focus when it matters most.

Formulated to help unlock extreme mental and physical performance, INSANITY Liquid Shock Energy Drinks take you from fatigued to a colossal jolt of energy with sharper focus, zero sugar and just five calories per can.

Inspired by the unrivaled intensity of BODi’s iconic INSANITY training series that millions of users have done over the last 17 years, this drink brings that same relentless intensity to every sip. INSANITY Liquid Shock Energy combines 300 mg of caffeine with TeaCrine® and Dynamine® in a triple-energy formula leveraging these plant-derived stimulant alkaloids for energy and focus. The result is a powerful energy experience that also features a blend of nootropic and performance ingredients designed to support sharper focus, faster reaction time and physical performance, delivering a major jolt of sustained energy.

“Our INSANITY fitness programs challenge people to achieve extraordinary physical and mental results,” said Carl Daikeler, Co-Founder and CEO of BODi. “We wanted an energy drink to match that next-level intensity, and this new INSANITY Liquid Shock Energy Drink delivers. Formulated to go far beyond caffeine alone and other energy drinks, INSANITY Liquid Shock provides an incredible range of performance benefits in a single serve can. We’ve taken the essence of our world-famous INSANITY fitness programs and formulated a powerful energy drink designed for high-intensity achievers, athletes, students, and gamers.”

Five Benefits. One Can. Four Flavors.

INSANITY Liquid Shock Energy Drink goes beyond energy alone, combining caffeine, nootropic and performance ingredients to support the demands of the body and mind.

Available in four unhinged flavors, including Nuclear Sherbet, Off Your Rocket, Radioactive Sour Apple, and Sourmelon Panic, the INSANITY Liquid Shock Energy Drink delivers:

  • A Colossal Jolt: Triple INSANITY energy – 300 mg of caffeine combined with TeaCrine ® and Dynamine ®.
  • Sharper Focus: Alpha-GPC, L-Tyrosine and caffeine to support sharper focus.
  • Reaction Time Support: A nootropic-focused formula to support mental sharpness and response.
  • Physical Performance: L-Citrulline, Betaine, Taurine and caffeine to support physical output.
  • Zero Sugar: Just five calories per can.

Expanding INSANITY and BODi’s Performance Nutrition Portfolio

On November 12, BODi will further expand the INSANITY brand into performance nutrition with the launch of INSANITY Pre-Workout Powder, timed to coincide with the debut of INSANITY: Unhinged, the all-new fitness program featuring three-time HYROX World Champion Hunter McIntyre, launching exclusively on BODi.

Featuring 360 mg of caffeine, TeaCrine®, Dynamine® and performance-focused ingredients, INSANITY Pre-Workout Powder is designed to support energy, endurance, focus, strength and pump for those who push to their limits and still wake up hungry for more.

The INSANITY Liquid Shock Energy Drink and INSANITY Pre-Workout Powder extend the brand into performance nutrition, supporting BODi’s broader portfolio alongside Shakeology, the P90X Supplement System and P90X Energy Drinks.

INSANITY Liquid Shock Energy is available now on BODi.com in a 12-pack case for $29.99which comes to just $2.50 per can. For a limited time, anyone who buys one case can get a second case 50% off. The product will soon be available on Amazon and at other retailers.

Together, these launches reflect BODi’s continued focus on nutrition and performance, extending its iconic fitness franchises into complementary products that support consumers beyond the workout.

To learn more and discover BODi’s entire performance nutrition portfolio, go to: BODi.com.

About BODi and The Beachbody Company

BODi is a proactive wellness company delivering nutrition, supplements, and proven fitness programs that help people take control of their health inside and out. With nearly three decades of experience, BODi, formerly Beachbody, has evolved from a leader in home fitness into a comprehensive health and fitness ecosystem designed to help people achieve their goals and lead healthier, more fulfilling lives. Anchored by science-backed nutrition solutions like Shakeology and supported by its portfolio of proven fitness and habit-building programs, including P90X and INSANITY, BODi is creating a more accessible and effective path to long-term health.

Since its inception, BODi has supported more than 30 million customers in achieving lasting results. The company continues to innovate across nutrition and digital fitness to deliver simple, proven solutions for modern lifestyles.

To subscribe and shop, visit BODi.com. For company and investor information, please visit TheBeachbodyCompany.com.

Media Relations:
[email protected]

Investor Relations:
[email protected]

Source: BODi

Release – Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

Posted on by [email protected]

October 21, 2026

PDF Version

SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (CMML).

“CMML remains a difficult-to-treat hematologic malignancy with limited treatment options for patients, and 40-50% of myeloproliferative CMML1 patients harbor RAS-pathway mutations, which are associated with more aggressive disease,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Receiving Orphan Drug Designation for onvansertib in CMML further validates the therapeutic potential of PLK1 inhibition in cancers with significant unmet need and adds to the growing body of evidence supporting this mechanism across both solid tumors and hematologic malignancies. We believe this designation highlights the broader clinical opportunity for onvansertib as a monotherapy as we continue advancing therapies for patients across cancers where new therapeutic approaches are urgently needed.”

Onvansertib is being evaluated in both company-sponsored and investigator-initiated clinical studies, including a Phase 1 investigator-initiated study in relapsed/refractory CMML. As presented at the 2025 American Society of Hematology (ASH) Annual Meeting, onvansertib was relatively well-tolerated as a monotherapy and demonstrated preliminary efficacy in approximately 40% of myeloproliferative CMML patients in the dose ranging trial. The responses included three patients experiencing clinical benefits (38%), with one each of the following: a 100% platelet response, normalization of White Blood Cells, WBC (baseline WBC count > 50 x 109/L), and spleen response. Additionally, one patient (12.5%) had optimal marrow response with bone marrow blast reduction from 8% to 2% facilitating for allogeneic hematopoietic stem transplant and 3 patients experienced stable disease (38%).

Orphan Drug Designation is granted by the FDA to support the development of therapies intended to treat rare diseases or conditions affecting fewer than 200,000 people in the United States. Benefits of the designation may include tax credits for qualified clinical trials, exemption from certain FDA user fees, and up to seven years of market exclusivity upon regulatory approval. Orphan Drug Designation does not alter the standard regulatory requirements or approval process.

About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor advancing toward a registrational trial in first-line RAS-mutated metastatic colorectal cancer (mCRC). In a randomized Phase 2 trial, onvansertib in combination with FOLFIRI/bevacizumab (first-line standard-of-care) demonstrated dose-dependent improvements in overall response rate and progression-free survival compared to standard-of-care alone, building on findings from a prior Phase 2 trial in second-line RAS-mutated mCRC. Based on these results, the Company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab as the regimen to advance into the planned registrational trial in first-line patients with RAS-mutated mCRC.

Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML).

About Chronic Myelomonocytic Leukemia
Chronic myelomonocytic leukemia (CMML) is a rare and aggressive hematologic malignancy characterized by features of both myelodysplastic syndromes and myeloproliferative neoplasms. CMML primarily affects older adults and is associated with poor clinical outcomes, including progressive bone marrow failure and risk of transformation to acute myeloid leukemia (AML). Current treatment options remain limited, highlighting the need for novel targeted therapies that can improve outcomes for patients with this disease.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Cardiff Oncology’s expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology’s Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Investor Contact:
Candice Masse
astr partners
[email protected]

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
[email protected]

Release – SKYX and Its Subsidiary Deako Announce They Will Supply Over 80,000 Units of Their Smart Home Technologies to Over 1,000 Homes of Prominent Home Builder Maronda Homes, as the Company Continues to Grow Its Market Penetration

Posted on by [email protected]

MIAMI, Oct. 21, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 120 patents and pending applications globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today announced that it will supply over 80,000 units of its advanced technologies to over 1,000 homes of prominent community and home builder Maronda Homes as it continues to grow its market penetration

Maronda Homes is a private, family-owned home builder founded in 1972 by William J. Wolf. Maronda has built over 70,000 homes across the United States and is currently building homes and communities across Florida, Ohio, Georgia, Alabama, Indiana, Kentucky, Maryland, Pennsylvania, South Carolina, Virginia, and West Virginia.

As a community and home builder many of Maronda Homes communities include resort-style pools and clubhouses to fitness centers, pickleball courts, dog parks, walking trails and playgrounds. Maronda communities are designed to bring families together.

The Company expects to deliver over 80,000 units of its advanced plug-and-play and smart home technologies to over 1,000 Maronda Homes residences in several states including Ohio, Georgia, Maryland, and Pennsylvania.

Maronda Homes offers a Certified Energy Efficient package designed to pair everyday comfort with smart home technology. Electrical and smart home package features may vary by market, community, and home.

For information about Maronda Homes, click here: www.marondahomes.com

For more information about SKYX and Deako, go to www.SKYX.com and www.Deako.com

Derek Richardson, Founder and CEO of Deako, stated: “This program with Maronda is a natural next step for Deako. Every new Maronda home in these communities starts with a smart home foundation that is simple for the builder to deliver and easy for the homeowner to grow. Pairing that package with the communities Maronda builds, from resort-style pools to walking trails, is the kind of home people are looking for, and it gives us a model we can repeat with builders across the country.”

Rani Kohen, Founder and Executive Chairman of SKYX Platforms, said: “We are very pleased to be working with such a prominent home builder, Maronda Homes. We expect to keep expanding our builder programs with our subsidiary Deako and look forward to continuing to grow our market penetration while creating safer, more advanced, and smarter homes and buildings of the future.”

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced, safe, smart and AI platform technologies, with over 120 U.S. and global patents and patent pending applications. Additionally, the Company owns 60 lighting and home décor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://www.skyx.com/ or follow us on LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts, but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s ability to achieve positive cash flows; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Investor Relations Contacts:

Jeff Ramson
PCG Advisory
[email protected]

Ronald A. Both
Encore Investor Relations
[email protected]

Cencora to Acquire American Oncology Network for $2.4 Billion in Major Cancer Care Expansion

Posted on by [email protected]

Cencora (NYSE: COR) has announced an agreement to acquire American Oncology Network (OTCQX: AONC) in a transaction valued at up to $2.4 billion, expanding the pharmaceutical distribution giant’s presence in community-based cancer care. The deal, announced October 21, 2026, will add a physician-led network of more than 350 oncology providers operating across 21 states to Cencora’s growing healthcare services platform.

The acquisition represents another significant step in Cencora’s strategy to expand beyond traditional pharmaceutical distribution and strengthen its relationships with healthcare providers. By integrating American Oncology Network’s clinical infrastructure and practice management capabilities, Cencora aims to support independent cancer specialists while improving patient access to advanced treatments.

Under the agreement, American Oncology Network is valued at $2.3 billion at closing, with an additional $100 million potentially payable through contingent value rights tied to specified conditions. Cencora already owns approximately 4% of the company and has agreed to acquire the remaining equity interests, subject to a potential ownership rollover by existing shareholders.

If eligible shareholders retain a combined 25% stake, Cencora expects to pay approximately $1.7 billion at closing to increase its ownership to 75%. The transaction remains subject to regulatory approvals, shareholder approval, and customary closing conditions.

Founded in 2018, American Oncology Network provides operational and administrative support to independent oncology practices, allowing physicians to concentrate on patient care. Its services include practice management, technology, and access to integrated healthcare resources designed to help smaller cancer treatment centers compete in an increasingly complex healthcare environment.

For Cencora, the acquisition expands its physician-led oncology management services organization into 12 additional states. The company expects the combination to create opportunities to strengthen cancer treatment delivery, expand practice support capabilities, and improve operational efficiency.

The transaction also highlights the growing importance of community oncology as cancer treatments become increasingly specialized and expensive. Independent oncology practices face mounting challenges involving reimbursement, drug procurement, technology investment, and administrative costs. Larger healthcare organizations are responding by building networks that provide centralized resources while allowing physicians to retain control over clinical decisions.

The expansion comes as biotechnology companies continue developing innovative cancer treatments that could eventually reach patients through community oncology practices. Companies such as Greenwich LifeSciences (NASDAQ: GLSI), which is developing an investigational immunotherapy for breast cancer, and MAIA Biotechnology (NYSE American: MAIA), which is advancing a telomere-targeting cancer treatment, illustrate the broader pipeline of emerging oncology therapies. Neither company is involved in the announced transaction.

For investors, the deal underscores how pharmaceutical distribution companies are seeking additional growth opportunities in specialized healthcare services. Expanding into oncology practice management could provide Cencora with deeper relationships across the cancer treatment market while supporting demand for pharmaceutical products and services.

Cencora expects the acquisition to contribute positively to adjusted diluted earnings per share beginning in the second year following completion. The company also raised its fiscal 2026 adjusted earnings outlook to at least $17.90 per share, reflecting strength in its U.S. Healthcare Solutions business.

The acquisition illustrates a broader shift toward integrated cancer care, where pharmaceutical distribution, clinical services, and healthcare technology increasingly operate within connected networks. As cancer treatments continue evolving, companies capable of supporting both drug delivery and community-based medical practices could play a larger role in shaping the future of oncology care.

NetSol Technologies, Inc. (NTWK) – Transcending to the Next Stage of Growth

Posted on by [email protected]


Wednesday, October 21, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage. We are initiating coverage of NetSol Technologies, a global provider of lending, leasing, and digital retail software to auto captives, banks, and equipment lenders. In our view, NetSol’s long-standing customer relationships and Transcend platform position it to benefit as lenders replace aging systems and to shift more revenue from one-time licenses to recurring subscriptions.

A record year. Fiscal 2026 revenue rose 12.5% to a record $74.4 million. Recurring subscription and support revenue grew 8.7% to $35.8 million and accounts for nearly half of total revenue. We believe the increased adoption of the Transcend platform’s subscription model should improve revenue visibility and reduce reliance on individual contract wins.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.